Total Payments
$7,077
2024 Payments
$39.25
Companies
20
Transactions
199
Medicare Patients
2,311
Medicare Billing
$413,199
Payment Breakdown by Category
Food & Beverage$6,492 (91.7%)
Education$385.30 (5.4%)
Consulting$200.00 (2.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,492 | 187 | 91.7% |
| Education | $385.30 | 10 | 5.4% |
| Consulting Fee | $200.00 | 2 | 2.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Products, LP | $1,852 | 17 | $0 (2023) |
| ViiV Healthcare Company | $1,181 | 37 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $962.66 | 30 | $0 (2021) |
| Gilead Sciences, Inc. | $535.75 | 18 | $0 (2024) |
| Janssen Biotech, Inc. | $478.55 | 29 | $0 (2022) |
| Allergan, Inc. | $417.02 | 17 | $0 (2020) |
| Astellas Pharma US Inc | $367.98 | 11 | $0 (2021) |
| Insmed, Inc. | $358.47 | 8 | $0 (2023) |
| Theravance Biopharma, Inc. | $243.32 | 13 | $0 (2018) |
| COMSORT, Inc | $200.00 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39.25 | 2 | Gilead Sciences, Inc. ($39.25) |
| 2023 | $596.53 | 8 | ViiV Healthcare Company ($391.17) |
| 2022 | $492.51 | 15 | ViiV Healthcare Company ($220.28) |
| 2021 | $605.81 | 17 | ViiV Healthcare Company ($227.38) |
| 2020 | $626.30 | 20 | Insmed, Inc. ($149.61) |
| 2019 | $1,171 | 35 | Janssen Products, LP ($350.58) |
| 2018 | $1,805 | 45 | Merck Sharp & Dohme Corporation ($468.86) |
| 2017 | $1,741 | 57 | Janssen Products, LP ($527.23) |
All Payment Transactions
199 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.81 | General |
| 05/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.44 | General |
| 12/09/2023 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: HIV | ||||||
| 07/17/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $8.20 | General |
| Category: HIV | ||||||
| 05/02/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $65.26 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/04/2023 | Janssen Products, LP | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $124.95 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 03/30/2023 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: HIV | ||||||
| 03/14/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $123.29 | General |
| Category: HIV | ||||||
| 02/08/2023 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $115.38 | General |
| Category: HIV | ||||||
| 01/11/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Respiratory | ||||||
| 11/01/2022 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Respiratory | ||||||
| 10/10/2022 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $9.98 | General |
| Category: HIV | ||||||
| 08/24/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: HIV | ||||||
| 08/10/2022 | Janssen Biotech, Inc. | PREZCOBIX (Drug) | Food and Beverage | In-kind items and services | $22.19 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 08/08/2022 | ViiV Healthcare Company | DOVATO (Drug), RUKOBIA | Food and Beverage | In-kind items and services | $10.58 | General |
| Category: HIV | ||||||
| 08/03/2022 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: Respiratory | ||||||
| 07/12/2022 | Janssen Products, LP | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $99.89 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 07/05/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: HIV | ||||||
| 05/27/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $3.67 | General |
| Category: HIV | ||||||
| 05/24/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $8.23 | General |
| Category: HIV | ||||||
| 04/21/2022 | Janssen Products, LP | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $116.31 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 04/15/2022 | ViiV Healthcare Company | RUKOBIA (Drug), DOVATO | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: HIV | ||||||
| 04/11/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $6.39 | General |
| Category: HIV | ||||||
| 03/31/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $113.31 | General |
| Category: HIV | ||||||
| 02/28/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $6.20 | General |
| Category: HIV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 290 | 997 | $154,950 | $70,231 |
| 2022 | 6 | 409 | 1,299 | $186,650 | $89,111 |
| 2021 | 6 | 608 | 1,293 | $197,200 | $96,436 |
| 2020 | 6 | 1,004 | 1,970 | $305,550 | $157,422 |
Total Patients
2,311
Total Services
5,559
Medicare Billing
$413,199
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 119 | 788 | $107,900 | $49,861 | 46.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 102 | 113 | $29,700 | $11,880 | 40.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 48 | $7,600 | $4,076 | 53.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 19 | $3,000 | $1,875 | 62.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,450 | $1,362 | 39.5% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 18 | 18 | $3,300 | $1,177 | 35.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 176 | 1,021 | $127,625 | $60,499 | 47.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 141 | 149 | $37,250 | $16,934 | 45.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 47 | $7,050 | $4,171 | 59.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 45 | $6,750 | $3,961 | 58.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 25 | 25 | $4,375 | $1,969 | 45.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $3,600 | $1,577 | 43.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 282 | 934 | $116,750 | $57,194 | 49.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 229 | 239 | $59,750 | $27,887 | 46.7% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 42 | 42 | $7,350 | $3,521 | 47.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 35 | $5,250 | $3,160 | 60.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 32 | $4,800 | $3,118 | 65.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $3,300 | $1,557 | 47.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 454 | 1,236 | $154,500 | $76,664 | 49.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 301 | 321 | $80,250 | $37,431 | 46.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 123 | 281 | $42,150 | $26,587 | 63.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 47 | 48 | $14,400 | $9,825 | 68.2% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 64 | 66 | $11,550 | $5,732 | 49.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 18 | $2,700 | $1,183 | 43.8% |
About Dr. Ramon Ramirez, MD
Dr. Ramon Ramirez, MD is a Infectious Disease healthcare provider based in Tamarac, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396844478.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ramon Ramirez, MD has received a total of $7,077 in payments from pharmaceutical and medical device companies, with $39.25 received in 2024. These payments were reported across 199 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($6,492).
As a Medicare-enrolled provider, Ramirez has provided services to 2,311 Medicare beneficiaries, totaling 5,559 services with total Medicare billing of $413,199. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Tamarac, FL
- Active Since 09/22/2006
- Last Updated 08/02/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1396844478
Products in Payments
- PREZCOBIX (Drug) $830.81
- ZERBAXA (Drug) $666.78
- SYMTUZA (Drug) $576.04
- Symtuza (Drug) $432.97
- CABENUVA (Biological) $399.50
- DOVATO (Drug) $398.22
- AVYCAZ (Drug) $283.71
- VIBATIV (Drug) $243.32
- Arikayce (Drug) $225.16
- DALVANCE (Drug) $225.04
- TRIUMEQ (Drug) $182.80
- Cresemba (Drug) $153.58
- RUKOBIA (Drug) $145.29
- ISENTRESS (Drug) $133.81
- DIFICID (Drug) $125.00
- CRESEMBA (Drug) $115.40
- VABOMERE (Drug) $114.62
- Biktarvy (Drug) $112.61
- ROTATEQ (Biological) $100.00
- XARELTO (Drug) $65.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.